NL-OMON39582已完成不适用
Continuation of Follow-up for Patients who were Previously Enrolled in the Clinical Study: *Open, Prospective Study to Evaluate the Safety and Preliminary Effectiveness of the BaroSense ACE Stapler for the Treatment of Obesity.* - Endoscopic plication study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 17
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Subject is willing and able to sign the Informed Consent Form (ICF).
- •2. Subject was previously enrolled in the *Open, prospective study to evaluate the safety and preliminary effectiveness of the BaroSense ACETM Stapler for the treatment of obesity (11-03)*.
排除标准
- •1. Subject is not willing and able to sign the ICF.
- •2. Subject was not previously enrolled in the *Open, prospective study to evaluate the safety and preliminary effectiveness of the BaroSense ACE Stapler for the treatment of obesity (11-03)*.
- •3. Subject is taking prescription or over-the-counter weight loss medications during the follow-up period.
- •4. Subject is taking anticoagulants or other medications which impede coagulation or platelet aggregation.
- •5. Subject is undergoing steroid or immunosuppressive therapy.
研究者
相似试验
进行中（未招募）
1 期
ong term follow up for patients who have received NiCord/CordIn, stem cells from donated umbilical cord bloodthat were grown in a laboratory to expand their numberHigh risk haematological malignanciesHemoglobinopathiesMedDRA version: 18.1Level: LLTClassification code 10025316Term: Lymphoma NOSSystem Organ Class: 100000004864MedDRA version: 18.1Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaSystem Organ Class: 100000004864MedDRA version: 18.1Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864MedDRA version: 18.1Level: LLTClassification code 10054658Term: ThalassemiaSystem Organ Class: 100000004850MedDRA version: 18.1Level: LLTClassification code 10009015Term: Chronic myeloid leukemiaSystem Organ Class: 100000004864MedDRA version: 18.1Level: LLTClassification code 10040645Term: Sickle cell disease NOSSystem Organ Class: 100000004850MedDRA version: 18.1Level: LLTClassification code 10028534Term: Myelodysplastic syndrome NOSSystem Organ Class: 100000004864EUCTR2015-004813-26-ESGamida Cell Ltd76
进行中（未招募）
1 期
Extension study for the follow up of patients with age related macula degeneration who participated in the Fase IV-II clinical trial randomized, simulated and blinded controlled treatment to evaluate safety and efficacy of a drug administered (etamsilato) via a needle in the eye. Clinical trial code OFT-ETAMSILATO -4.2.1EUCTR2015-001812-36-ESDr. Pedro Cuevas Sanchez (Investigacion Independiente)44
尚未招募
不适用
ong-Term Follow-Up of Patients who have received an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (TX200-TR101) in a prior clinical study.Renal transplant rejectionAllograft rejection1002766510029149NL-OMON56013Sangamo Therapeutics France SAS8
进行中（未招募）
1 期
ong-Term Follow-Up of Patients who have received an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (CAR- Treg therapy, TX200-TR101) in a prior clinical study.Prevention of immune mediated allograft rejection in patients with end-stage renal disease (ESRD) who are tissue typed as HLA-A*02 negative and have received a kidney transplant from an HLA-A*02 positive living donor.MedDRA version: 21.1Level: LLTClassification code 10050436Term: Prophylaxis against renal transplant rejectionSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2022-002440-40-DESangamo Therapeutics France SAS15
招募中
1 期
ong-Term Follow-Up of TX200-TR101 (STEADFAST Long Term)Kidney Transplant RejectionMedDRA version: 21.1Level: LLTClassification code: 10050436Term: Prophylaxis against renal transplant rejection Class: 10042613CTIS2024-512580-31-00Sangamo Therapeutics France30